Response to Comments: MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

This notice documents the response to comments for the MolDX LCD L38972 and announces administrative changes: comment period 05/20/2021–07/31/2021, notice period beginning 06/23/2022, and an effective date of 08/08/2022. The LCD title was revised from "MolDX: Next-Generation Sequencing Lab-Developed Tests for Inherited Cancer Syndromes" to "MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer." This document does not contain clinical coverage criteria; refer to LCD L38972 for specific indications, limitations, documentation, and frequency rules.